Is real‐life hepatitis C virus therapy as effective as in clinical trials?

Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration

“…However, several remaining challenges such as DAA cost and treatment of HCV in special populations must be overcome to achieve this goal [ 2 , 3 ]. Shortening duration of DAA therapy could provide cost savings [ 4–7 ], reduce medication exposure (eg, during pregnancy [ 8 ]), and help to foster adherence and treatment completion in general [ 9 ] and specifically in special populations (eg, people who inject drugs [ 2 ] and incarcerated individuals [ 10 ]), which is key to achieving cure [ 11 ]. Thus, identifying individuals for shortening DAA therapy duration is warranted.…”